ESTRO 2024 - Abstract Book

S5992

RTT - Treatment planning, OAR and target definitions

ESTRO 2024

Keywords: OAR, CONTOURING, PROTON THERAPY

References:

Frezza, Anna Maria; Botta, Laurab; Trama, Annalisab; Dei Tos, Angelo P.c,d; Stacchiotti, Silviaa. Chordoma: update on disease, epidemiology, biology and medical therapies. Current Opinion in Oncology: March 2019 - Volume 31 - Issue 2 - p 114-120 doi: 10.1097/CCO.0000000000000502 Zou KH, Warfield SK, Bharatha A, Tempany CM, Kaus MR, Haker SJ, Wells WM 3rd, Jolesz FA, Kikinis R. Statistical validation of image segmentation quality based on a spatial overlap index. Acad Radiol. 2004 Feb;11(2):178-89. doi: 10.1016/s1076-6332(03)00671-8. PMID: 14974593; PMCID: PMC1415224. Fedorov A., Beichel R., Kalpathy-Cramer J., Finet J., Fillion-Robin J-C., Pujol S., Bauer C., Jennings D., Fennessy F.M., Sonka M., Buatti J., Aylward S.R., Miller J.V., Pieper S., Kikinis R.3D Slicer as an Image Computing Platform for the Quantitative Imaging Network. Risonanza magnetica. 2012 Novembre;30(9):1323-41. PMID: 22770690. PMCID: PMC3466397.

1989

Proffered Paper

Daily Organs-At-Risk Variations and Their Impact on Dose Target Coverage in Pancreatic Tumors

Myrian Rinzema, Miguel A. Palacios, Omar Bohoudi, Eva Versteijne, Anna M.E. Bruynzeel

Amsterdam UMC, Radiation Oncology, Amsterdam, Netherlands

Purpose/Objective:

Pancreatic tumors pose a significant challenge in the field of radiotherapy due to the proximity of organs at risk (OAR) to the tumor. Pancreatic cancer patients benefit from Magnetic Resonance Imaging guided radiotherapy (MRIgRT) because of the excellent soft tissue contrast and the ability to adapt online the original treatment plan based on the anatomy of the day. In this work, we studied the variation in target and organs at risk (OAR) volumes and its effect on target coverage in MRIgRT for pancreatic tumors.

Material/Methods:

Data from patients with pancreatic tumors treated at our institution between 2018 and 2023 were extracted from our institutional database. A total of 92 patients and 453 fractions delivered with MRIgRT comprised the complete dataset. Patients were treated with a treatment schedule of 5 fractions of 8Gy, for a total dose of 40Gy. Seven patients were unable to finish the course of treatment, these fractions were not included.